Center for Advanced Practice
Title
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
Publication Title
Nature medicine
Document Type
Article
PubMed ID
31263281
Abstract
The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations
Keywords
Adult, Animals, Child, Female, HEK293 Cells, Humans, Lymphatic Abnormalities, Male, Mitogen-Activated Protein Kinase Kinases, Mutation, Proto-Oncogene Proteins A-raf, Pyridones, Pyrimidinones, Exome Sequencing, Zebrafish
DOI
10.1038/s41591-019-0479-2
Publication Date
7-1-2019
Citation
Li, D., March, M., Gutierrez-Uzquiza, A., Kao, C., Seiler, C., Pinto, E., Matsuoka, L., Battig, M., Bhoj, E., Wenger, T., Tian, L., Robinson, N., Wang, T., Liu, Y., Weinstein, B., Swift, M., Jung, H., Kaminski, C., Chiavacci, R., Perkins, J., Levine, M., Sleiman, P., Hicks, P., Strausbaugh, J., Belasco, J., Dori, Y., & Hakonarson, H. (2019). ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.. Nature medicine, 25 (7), 1116-1122. https://doi.org/10.1038/s41591-019-0479-2
